论文部分内容阅读
将我院2014年7月-2015年6月收治的78例早期糖尿病肾病患者随机均分为观察组(n=39)和对照组(n=39)。在常规性控制血糖等治疗的基础上,观察组患者给予辛伐他汀和厄贝沙坦,对照组患者给予厄贝沙坦治疗,持续12周。结果:治疗后观察组患者舒张压(DBP)、收缩压(SBP)、空腹血糖(FBG)、尿β2微球蛋白(β2-MG)、尿白蛋白排泄率(UAER)、总胆固醇(TC)、甘油三酯(TG)均明显下降,与治疗前相比,差异有统计学意义(P<0.05),血肌酐(SCr)较治疗前无明显变化(P>0.05)。对照组患者DBP、SBP、FBG、UAER、β2-MG明显下降,TG、TC、SCr较治疗前无明显变化(P>0.05);治疗后观察组UAER、β2-M G、TG、TC均显著低于对照组治疗后,差异有统计学意义(P<0.05)。两组患者均出现1例不良反应情况,差异无统计学意义(P>0.05)。结论:辛伐他汀联合厄贝沙坦治疗早期糖尿病肾病取得了良好的临床效果,可以更好的降低患者的尿白蛋白,血脂,保护肾功能,且临床安全性高。
78 patients with early diabetic nephropathy admitted in our hospital from July 2014 to June 2015 were randomly divided into observation group (n = 39) and control group (n = 39). On the basis of routine control of blood glucose and other treatments, patients in the observation group were given simvastatin and irbesartan, and patients in the control group were treated with irbesartan for 12 weeks. Results: After treatment, DBP, SBP, FBG, β2-MG, UAER and TC in the observation group were significantly higher than those in the control group , Triglyceride (TG) were significantly decreased compared with before treatment, the difference was statistically significant (P <0.05), serum creatinine (SCr) had no significant change compared with before treatment (P> 0.05). The levels of DBP, SBP, FBG, UAER and β2-MG in the control group were significantly lower than those in the control group (P> 0.05). The levels of UAER, β2-MG, TG and TC in the observation group were significantly lower In the control group after treatment, the difference was statistically significant (P <0.05). One case of adverse reactions occurred in both groups, with no significant difference (P> 0.05). Conclusion: Simvastatin combined with irbesartan in the treatment of early diabetic nephropathy has achieved good clinical results, which can better reduce urinary albumin, blood lipids, protect renal function, and high clinical safety.